Exenatide Once Weekly Versus Daily Basal Insulin as Add-on Treatment to Metformin With or Without a Sulfonylurea: A Retrospective Pooled Analysis in Patients With Poor Glycemic Control

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Postgraduate medicine

• Publication date

  2013-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3810/pgm.2013.09.2704PMID 24113668
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir

  2013cited by this paper
• Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

  2013cited by this paper
• Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379

  2013cited by this paper
• Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years

  2013cited by this paper
• Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

  2012cited by this paper
• Determining predictors of response to exenatide in type 2 diabetes.

  2012cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cited by this paper
• DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

  2011cited by this paper
• Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program.

  2011cited by this paper
• Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.

  2010cited by this paper
• Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.

  2010cited by this paper
• Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.

  2009cited by this paper
• One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients

  2009cited by this paper
• Relationship of baseline HbA1c and efficacy of current glucose‐lowering therapies: a meta‐analysis of randomized clinical trials

  2009cited by this paper
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

  2009cited by this paper
• Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

  2009cited by this paper
• Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.

  2008cited by this paper
• Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.

  2007cited by this paper
• Lower Baseline Glycemia Reduces Apparent Oral Agent Glucose-Lowering Efficacy

  2006cited by this paper
• Exenatide Versus Insulin Glargine in Patients With Suboptimally Controlled Type 2 Diabetes: A Randomized TrialHeine RJ, for the GWAA Study Group (VU Univ, Amsterdam; et al) Ann Intern Med 143:559–569, 2005§

  2006cited by this paper
• Triple Therapy in Type 2 Diabetes: Insulin Glargine or Rosiglitazone Added to Combination Therapy of Sulfonylurea Plus Metformin in Insulin-Naïve Patients

  2006cited by this paper
• Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes

  2005cited by this paper

• Insulin Versus Established GLP-1 Receptor Agonists, DPP-4 Inhibitors, and SGLT-2 Inhibitors for Uncontrolled Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2025cites this paper
• A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal‐bolus insulin or a glucagon‐like peptide‐1 receptor agonist plus basal insulin: The SIMPLE study

  2019cites this paper
• Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials

  2017cites this paper
• Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points

  2015cites this paper
• Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus

  2015cites this paper
• Esperienza Clinica: passaggio da terapia insulinica a Exenatide Lar Once Weekly in diabetici obesi ad alto rischio cardiovascolare

  2015cites this paper
• Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.

  2014cites this paper